Emergence of multiple resistance profiles involving azoles, echinocandins and amphotericin B in Candida glabrata isolates from a neutropenia patient with prolonged fungaemia

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 4, 2014, Pages 1268-1270

  Cho, Eun Jung ^a   Shin, Jong Hee ^b   Kim, Soo Hyun ^b   Kim, Hyun Ki ^a   Park, Jeong Su ^a   Sung, Heungsup ^a   Kim, Mi Na ^a   Im, Ho Joon ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

Antifungal resistance; Caspofungin; FKS2; Micafungin

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE; ANTIFUNGAL AGENT; PYRROLE DERIVATIVE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ANTIMICROBIAL THERAPY; BLOOD CULTURE; CANDIDA GLABRATA; CANDIDEMIA; CASE REPORT; CHRONOTHERAPY; FEBRILE NEUTROPENIA; FUNGUS ISOLATION; HUMAN; LETTER; LEUKEMIA RELAPSE; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; URINE CULTURE; COMPLICATION; DNA SEQUENCE; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR GENETICS; NEUTROPENIA;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; CANDIDA GLABRATA; CANDIDEMIA; ECHINOCANDINS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; NEUTROPENIA; SEQUENCE ANALYSIS, DNA;

EID: 84926506820     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku518     Document Type: Letter

References (11)

1. Pfaller MA, Messer SA, Woosley LN et al. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 2013; 51: 2571-81.
2. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Third Edition: Approved Standard M27-A3. CLSI, Wayne, PA, USA, 2008.
3. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Fourth Informational Supplement M27-S4. CLSI, Wayne, PA, USA, 2012.
4. Alexander BD, Johnson MD, Pfeiffer CD et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013; 56: 1724-32.
5. Shin JH, Chae MJ, Song JWet al. Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia. J Clin Microbiol 2007; 45: 2385-91.
6. Chapeland-Leclerc F, Hennequin C, Papon N et al. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother 2010; 54: 1360-2.
7. Hull CM, Bader O, Parker JE et al. Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2. Antimicrob Agents Chemother 2012; 56: 6417-21.
8. Fidel PL, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999; 12: 80-96.
9. PfallerMA, CastanheiraM, Lockhart SR et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50: 1199-203.
10. Shin JH, Kim MN, Jang SJ et al. Detection of amphotericin B resistance in Candida haemulonii and closely related species by use of the Etest, Vitek-2 yeast susceptibility system, and CLSI and EUCAST broth microdilution methods. J Clin Microbiol 2012; 50: 1852-5.
11. Sanglard D, Ischer F, Parkinson T et al. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother 2003; 47: 2404-12.